Ensign Peak Advisors
BLUE

Ensign Peak Advisors’s bluebird bio BLUE Stock Holding History

Ensign Peak Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,543
Closed -$211K – 2313
2022
Q2 		$211K Buy
2,543
+1,085
+74% +$84.1K ﹤0.01% 1779
2022
Q1 		$141K Buy
1,458
+212
+17% +$28K ﹤0.01% 1961
2021
Q4 		$249K Buy
+1,246
New +$294K ﹤0.01% 1875

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ensign Peak Advisors's BLUE Position: Q3 2022 in Review

Ensign Peak Advisors sold out of bluebird bio (BLUE) in Q3 2022, closing a stake of 2,543 shares — an estimated $211K sold.

Ensign Peak Advisors first reported a position in BLUE in Q4 2021 and held it in 3 quarters. The position peaked at $249K in Q4 2021. 162 funds tracked by Wall St. Rank hold BLUE as of Q3 2022.

  • Ensign Peak Advisors reported no remaining bluebird bio position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 2,543 bluebird bio shares in Q3 2022, an estimated $211K.
  • Ensign Peak Advisors first reported a position in bluebird bio in Q4 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's bluebird bio position peaked at $249K in Q4 2021.
  • 162 funds tracked by Wall St. Rank held bluebird bio as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.